Uses of viral vectors have thus far eclipsed uses of non-viral vectors for gene therapy
delivery in the clinic. Viral vectors, however, have certain issues involving genome …

In the two decades since their initial discovery, DNA vaccines technologies have come a
long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still …

DNA vaccines have emerged as innovative approaches that have great potential to
overcome the limitations of current conventional vaccines. Plasmid DNA vaccines are often …

Cancer is an extremely complex disease involving multiple signaling pathways that enable
tumor cells to evade programmed cell death, thus making cancer treatment extremely …

DNA vaccination is a disruptive technology that offers the promise of a new rapidly deployed
vaccination platform to treat human and animal disease with gene-based materials …

For patients with hereditary retinal diseases, retinal gene therapy offers significant promise
for the prevention of retinal degeneration. While adeno-associated virus (AAV)-based …

Introduction: Nucleic-acid-based biopharmaceuticals enclose a remarkable potential for
treating debilitating or life-threatening diseases that currently remain incurable. This …

The co-delivery of minicircle DNA (mcDNA) and small anti-cancer drugs via stimuli-sensitive
nanocarriers is a promising approach for combinatorial cancer therapy. However, the …

Gene therapy for cystic fibrosis using non-viral, plasmid-based formulations has been the
subject of intensive research for over two decades but a clinically viable product has yet to …

Chimeric antigen receptor (CAR) therapy has achieved remarkable clinical efficacy against
hematological cancers and has been approved by FDA for treatment of B-cell tumors …